Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

NCT06613685 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

73

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to terminate study.

Conditions

HIV-1-infection

Interventions

DRUG: lepetegravir
DRUG: lenacapavir pacfosacil
DRUG: Bictegravir/emtricitabine/tenofovir alafenamide
DRUG: lepetegravir/lenacapavir pacfosacil FDC
DRUG: Placebo to Match BVY
DRUG: Placebo to Match GS1720/GS-4182 FDC

Sponsor

Gilead Sciences